Loading…
Loading…
EQUITY / NASDAQ · XNCM
Outlook Therapeutics Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.593 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 0.593 USD · Volume 5,619,613
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 3 | 2025 / Quarter 3 | Change |
|---|---|---|---|
| Operating profit | -10,810,209 USD | -15,748,680 USD | — |
| Net income | -20,319,272 USD | -20,152,502 USD | — |
| Cash and cash equivalents | 11,242,068 USD | — | — |
| Total liabilities | 36,577,417 USD | — | — |
| Total equity | -10,392,567 USD | -37,189,725 USD | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 304/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 301/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 210/01/2025 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 309/30/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Year end10/01/2024 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 304/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 11,242,068 USD | — | — | — | — | 8,083,085 USD | 8,083,085 USD | — |
| Gross profitIncome statement | -8,265 USD | -1,267,612 USD | — | -1,259,347 USD | — | — | 57,205 USD | 1,065,507 USD |
| Net incomeIncome statement | -20,319,272 USD | -47,830,487 USD | -4,453,081 USD | -27,511,216 USD | -23,058,135 USD | — | -62,424,863 USD | -20,152,502 USD |
| Operating profitIncome statement | -10,810,209 USD | -38,321,148 USD | — | -27,510,939 USD | — | — | -67,061,666 USD | -15,748,680 USD |
| Total assetsBalance sheet | 26,184,850 USD | — | — | — | — | 18,584,183 USD | 18,584,183 USD | — |
| Total equityBalance sheet | -10,392,567 USD | — | -28,994,771 USD | — | -38,549,465 USD | -32,187,661 USD | -32,187,661 USD | -37,189,725 USD |
| Total liabilitiesBalance sheet | 36,577,417 USD | — | — | — | — | 50,771,844 USD | 50,771,844 USD | — |
| Financing cash flowCash flow statement | — | 49,036,671 USD | — | 22,432,307 USD | — | — | 44,984,984 USD | — |
| Investing cash flowCash flow statement | — | -2,100,000 USD | — | — | — | — | — | — |
| Operating cash flowCash flow statement | — | -43,777,688 USD | — | -22,767,166 USD | — | — | -51,829,437 USD | — |
| RevenueIncome statement | — | — | — | — | — | — | 1,413,535 USD | — |
| Report source | Open report ↗ Published: 08/18/2026 | Open report ↗ Published: 08/18/2026 | Open report ↗ Published: 08/18/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 08/18/2026 | Open report ↗ Published: 08/18/2026 | Open report ↗ Published: 12/19/2025 | Open report ↗ Published: 08/18/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.